Rapid increase in lymphogranuloma venereum in men who have sex with men, United Kingdom, 2003 to September 2015

T Childs, I Simms, S Alexander, K Eastick, G Hughes, N Field

1. HIV and STI Department, Public Health England Health Protection Services, Colindale, United Kingdom
2. Sexually Transmitted Bacteria Reference Unit, Public Health England Reference Microbiology Services, Colindale, United Kingdom
3. Scottish Bacterial Sexually Transmitted Infections Reference Laboratory, Edinburgh Royal Infirmary, Edinburgh, United Kingdom
4. Department of Infection and Population Health, University College London, London, United Kingdom

Correspondence: Nigel Field (nigel.field@phe.gov.uk)

Citation style for this article:

United Kingdom (UK) national data show a sharp increase in diagnoses of lymphogranuloma venereum (LGV) since 2012. Most cases are in men who have sex with men (MSM) living in London, with high rates of co-infection with HIV and other sexually transmitted infections. In light of these data, and the recent finding that one quarter of LGV infections may be asymptomatic, clinicians should be vigilant in testing for LGV, including in asymptomatic HIV-positive MSM.

Laboratory diagnoses of lymphogranuloma venereum (LGV) in the United Kingdom (UK) declined between 2010 and 2012, but the most recent data show near doubling of cases since 2012 to unprecedented levels in 2014 (679 cases). This trend has continued into 2015, with 683 cases diagnosed by 30 September. In 2014, most cases were in men who have sex with men (MSM) and around three quarters were HIV-positive. Here we report national surveillance data showing trends in LGV diagnoses in the UK from 2003 to September 2015.

Testing protocol and data sources
Rectal, genital or urine samples from patients with symptoms compatible with LGV and diagnosed with Chlamydia trachomatis in England, Wales and Northern Ireland, and their sexual contacts with C. trachomatis, are submitted by local laboratories for LGV typing to the Public Health England national reference laboratory, the Sexually Transmitted Bacteria Reference Unit (STBRU) in London. Scottish samples from symptomatic patients are similarly submitted to the Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) in Edinburgh. In addition, since 2007, samples from asymptomatic HIV-positive MSM diagnosed with C. trachomatis are also sent to SBSTIRL. During the reporting period, (January 2003 to September 2015) STBRU and SBSTIRL diagnoses accounted for all confirmed LGV cases diagnosed in the UK. Duplicates were excluded and repeat diagnoses within 42 days (used to define a single episode of care across surveillance systems in England) were counted as a single episode [1].

Additional data, including sexual behaviour and clinical information, were collected through nationally coordinated enhanced surveillance of LGV in the UK between 2004 and 2010 [2]. However, the most recent laboratory dataset lacks this enhanced information. We therefore matched laboratory reports for LGV diagnoses to the Genitourinary Medicine Clinic Activity Dataset (GUMCADv2), an anonymised patient-level electronic dataset, for all cases in England in 2014. All commissioned sexual health services in England have been mandated to return GUMCADv2 data, which include patient characteristics, other sexually transmitted infection (STI) diagnoses and services provided, since 2009 [3]. A code for LGV diagnosis was introduced in 2011, such that most cases are now reported through GUMCADv2. LGV diagnoses in female or heterosexual male patients in GUMCADv2 were excluded from this analysis because they may represent miscoding (six cases).

Trends in confirmed laboratory reports
Between 1 January 2003 and 30 September 2015, there were 4,124 LGV diagnoses in the UK (36 from Scotland since 2011). Of these, 4,111 (99.7%) were in men, and 242 had repeat diagnoses. LGV was first reported in the UK in 2003 (one case) and in 2004, 28 cases were reported (Figure).
Since 2003, the overall trend in LGV cases has been upward, with three rapid increases in 2005 (220 cases), 2010 (510 cases) and 2014 (679 cases), and intervening periods of stable or falling numbers between 2006 and 2009 (136 to 201 cases) and 2011 and 2012 (389 and 376 cases). There has been a sustained increase in diagnoses since 2012, such that diagnoses in 2014 were 81% higher than in 2012 (376 cases), and in the first quarter of 2015, there were 195 LGV diagnoses compared with 163 diagnoses in the same time period in 2014.

Case characteristics among clinical reports
In 2014, 11,468 diagnoses of *C. trachomatis* among MSM and 633 LGV cases were reported to GUMCADv2. Of the LGV cases, 434 (69%) could be matched to the laboratory dataset. Among the matched MSM cases, the median (IQR) age at LGV diagnosis was 37 (range: 31–44) years, and most were white (320, 74%), born in the UK (239, 55%) and living in London (323, 74%). Most cases were HIV-positive (321, 74%) and of these, nearly all were diagnosed with HIV before or at the same time as their LGV diagnosis (313, 98%). Many patients were diagnosed with another STI or blood borne virus infection at any time during 2014 (272, 63%), including gonorrhea (219, 50%), syphilis (76, 18%) and hepatitis C (13, 3%) (Table).

Background
LGV is a STI caused by the invasive L serovars of *C. trachomatis*. An outbreak among MSM was first reported in the Netherlands in 2003 and LGV outbreaks in MSM have since been reported by many high-income countries, with HIV co-infection being a common feature [4-8]. Most reported infections are rectal, and the most common presentation is proctitis, associated with rectal pain, discharge and bleeding [5,9]. Some cases of LGV, particularly in the beginning of the outbreak, were misdiagnosed as Crohn’s disease [10,11]. The complications of incorrectly treated or untreated LGV are serious, particularly for immunocompromised individuals, including genital ulcers, fistulas, rectal strictures and genital elephantiasis. LGV acquisition is associated with concurrent STI infections and reported behaviours such as condomless anal intercourse, fisting and the use of sex toys [2].

Discussion
Since 2003, LGV diagnoses have increased over a twelve-year period, with a steep rise since 2012, to reach unprecedented levels in 2015, suggesting high levels of ongoing transmission. Infection remains concentrated in white MSM living in London, many with HIV co-infection and other STIs.
The strength of this study lies in the unique national dataset of laboratory confirmed LGV diagnoses, which we linked to clinical data for the most recent complete year. During the study period, LGV testing was only recommended for symptomatic patients and LGV contacts. However, a large multicentre case-finding study in the UK found that 27% of LGV infections were detected in patients without rectal symptoms, suggesting that infections might be missed [12,13]. Patients might also be treated presumptively without LGV testing or never seek care, leading to further underestimation of LGV cases in the population. Other external factors might have influenced requests for LGV testing and the trends observed. These include the introduction of charging laboratories for LGV diagnostic testing (April 2014) and increased awareness of LGV among clinicians and microbiologists, which might have led to increased testing. We lack data on symptoms associated with LGV infection in this surveillance dataset.

The increase in LGV diagnoses coincides with upward trends in other STIs and sexually transmissible enteric infections among MSM, such as gonorrhoea, infectious syphilis, verotoxin-producing *Escherichia coli* and *Shigella* [14-17]. Contributory factors might include sexual networks with high rates of partner change facilitated by social media networking sites and chemsex, and we know that HIV-positive MSM who engage in sero-adaptive behaviours and have condomless sex with other HIV-positive men remain at particularly high risk [15-17]. Our data suggest a need for a strengthened public health response to raise awareness of LGV among clinicians and patients. Social media might offer a means of rapid, low-cost dissemination of public health messages, with an additional benefit of facilitating user interaction [18].

There are also important implications for clinical management and microbiologists, including the need for robust partner notification, testing and treatment, and testing of HIV-positive MSM with asymptomatic *C. trachomatis* infection for LGV [19]. LGV treatment requires an extended course of antibiotics over non-LGV *C. trachomatis*, such that some patients may unnecessarily receive multiple courses of antibiotics; this risks introducing selection pressure for antimicrobial resistance [20]. Clinicians should maintain a high index of suspicion for LGV in HIV-positive MSM with rectal symptoms, and consider treating presumptively for LGV according to national guidelines [21,22].

### Acknowledgements

We would like to thank members of the LGV Incident Group, past and present, and all clinicians who reported to enhanced LGV surveillance. We also thank all members, past and present, of the Public Health England Sexually Transmitted Bacteria Reference Unit who have been involved in processing specimens, and of the HIV and STI department involved in the processing and analysis of enhanced LGV surveillance data. Past and present members of the LGV Incident Group: Barry Evans, Kevin Fenton, Heather Jebbari, (HIV &...
STI Department, Public Health England Colindale); Patrick French (Mortimer Market Centre, London); Gillian Dean, Andy Parkhouse, Zoe Warwick and Iain Reeves (Claude Nicol Centre, Brighton); Anne Sullivan, Sanjeewa Pallawela, Gary Seaton, James Hardie and Naa Torshie Annan (Chelsea and Westminster Hospital, London); Neil Irvine (Health Protection Agency Northern Ireland); John White (Guys and St Thomas’s Hospital Trust, London); Neil Macdonald (Imperial College London, London); Andy Winter (HIV and Genitourinary Medicine, Sandysford Initiative, Glasgow); Lesley Wallace (Health Protection Scotland); Daniel Thomas and Gemma Northey (National Public Health Service for Wales); Alexander Macmillan and Dan Clutterbuck (Edinburgh Royal Infirmary); Ben Tunstall, Marc Thompson and Rod Watson (Terrence Higgins Trust); Helen Maguire, Paul Cook and Josh Forde (Public Health England London Epidemiology Unit); Lorraine Hickey (HSE, Republic of Ireland).

Conflict of interest

None declared.

Authors’ contributions

TC, IS, GH, and NF drafted the manuscript. TC undertook data analysis assisted by SA and KE. All authors contributed to data interpretation and revised the manuscript.

References


www.eurosurveillance.org